What is Migre Lief^TM?

Formulated by leading researchers in the fields of natural medicine and nutrition, Migre Lief^TM is the first comprehensive supplement for the support of cerebrovascular tone.* Using a botanical extract and nutritional supplements in the amounts shown beneficial in scientific studies, Migre Lief^TM provides the healthcare professional with a valuable tool for patients seeking a dietary supplement to help support normal cerebrovascular tone.*

PRODUCT DESCRIPTION

Migre Lief^TM is a unique combination of herbal and nutritional supplements aimed at supporting cerebrovascular tone, and reducing platelet aggregation and the production of pro-inflammatory mediators.* The herbal and nutritional ingredients in Migre Lief^TM are used in the amounts shown to be beneficial in scientific studies.*

Feverfew
Commonly recommended for its ability to support cerebrovascular tone, feverfew (Tanacetum parthenium) is rich in compounds known as sesquiterpene lactones. The most important of these compounds is parthenolide, which represents 85% of the sesquiterpene lactone content in feverfew leaf extracts. Particularly important in feverfew extracts is the parthenolide content as well as the stability of this important constituent. Migre Lief^TM is not only standardized to a high parthenolide content of 0.7% but also measures the stability of parthenolide. Standardization insures the optimal dosage of parthenolide in an extract that will not lose its potency over time. Scientific studies have found parthenolide inhibits platelet aggregation and the release of serotonin from platelets and polymorphonuclear leukocyte granules.* It has also been shown to inhibit pro-inflammatory prostaglandin synthesis and the release of arachadonic acid.* European studies have shown the benefits of a feverfew extract, standardized on parthenolide content, on the long-term support of cerebrovascular tone.*

Magnesium is a nutritional supplement with numerous effects that support vascular tone.* These include: 1) inhibition of platelet aggregation;2) interference with synthesis, release, and action of inflammatory mediators;3) direct alterations of cerebrovascular tone; 4) inhibition of vasospasm; and 5) stabilization of cell membranes.* Some persons with poor cerebrovascular tone have been found to have low brain levels of magnesium.* Recommended daily dosages of magnesium typically range from 200 to 600 mg to compensate for this deficiency.*

Riboflavin (vitamin B-2) is a precursor of flavin adenine dinucleotide(FAD). This coenzyme is an important component of the electron-transport chain. A deficiency of mitrochondrial energy reserves has been observed in some persons exhibiting poor cerebrovascular tone. This defect may theoretically be corrected by a compound such as riboflavin that improves the activity of the electron-transport chain.**These statements have not been evaluated by the Food and Drug Administration.   This product is not intended to diagnose, treat, cure, or prevent any disease.*

INGREDIENTS

Two Caplets Provide: Amount% of U.S. RDA*
Feverfew (Tanacetum parthenium) Extract..........100 mg. (Standardized to 0.7% Parthenolide) Magnesium (Citrate/Oxide 1:1)..........................300 mg............................75
Riboflavin (Vitamin B-2).....................................400 mg............................23,525 *

Percentage of U.S. Recommended Daily Allowance Contains no yeast, milk, corn, wheat, gluten, soy sodium, salt, sugar,flavorings, preservatives, artificial colors. This product is not intended to diagnose, treat, cure or prevent any disease.

RECOMMENDED USE
Take one caplet twice daily. Migre Lief^TM is designed to provide benefits within four to six weeks. Once results are noted, Migre Lief^TM may be used as part of a daily supplement regime and comprehensive wellness program. Each bottle contains a 4 week supply.

CONTRAINDICATIONS, ADVERSE REACTIONS OR INTERACTIONS
Side effects due to any of the ingredients in Migre Lief^TM are rare. Mild gastrointestinal upset and loose stools may occur in some persons using magnesium. This product is not recommended for use during pregnancy or lactation and should not be used in children under the age of two years. Persons taking potassium-sparing diuretics or with renal failure should not use this product.

SELECTED REFERENCES
Brown D, Gaby A, Reichert R. Clinical Applications of Natural Medicine--Migraine. NPRC Condition-Specific Monograph Series, 1997.

Feverfew. Lawrence Review of Natural Products, September 1994.

Awang DVC. Herbal Medicine, Feverfew. Canadian Pharm J 1989; 122:266-70.

Heptinstall S, Awang DVC, Dawson BA, et al. Parthenolide Content and Bioactivity of Feverfew (Tanacetum parthenium). Estimation of Commercial and Authenticated Feverfew Products. J Pharm Pharmacol 1992; 44:391-5.

Pugh WJ, Sambo K. Prostaglandin Synthetase Inhibitors in Feverfew. J Pharm Pharmacol 1988; 40-743-5.

Heptinstall S, White A, Williamson L, Mitchell JRA. Extracts of Feverfew Inhibit Granule Secretion in Blood Platelets and Polymophonuclear Leukocytes. Lancet 1985; i:1071-4.

Makheja AN, Bailey JM. A Platelet Phospholipase Inhibitor from the Medicinal Herb Feverfew (Tanacetum parthenium). Prostagland Leukotrienes Med 1982;8:653-60.

Sumner H, Salan U, Knight DW, Hoult JRS. Inhibition of 5-Lipoxygenase and Cyclo-oxygenase in Leukocytes by Feverfew. Biochem Pharmacol 1992;43:2313-20.

Johnson ES, Kadam NP, Hylands DM, Hylands PF. Efficacy of Feverfew As prophylactic Treatment of Migraine. British Med J 1985; 291:569-73.

Murphy JJ. Heptinstall S, Mitchell JRA. Randomized Double-Blind Placebo-Controlled Trial of Feverfew in Migraine Prevention. Lancet 1988; ii:189-92.

Altura BM. Calcium Antagonist Properties of Magnesium: Implications for Anti-migraine Actions. Magnesium 1985; 4:169-75.

Ramadan NM, Halvorson H, Vande-Linde A, et al. Low Brain Magnesium in Migraine. Headache 1989; 29:590-93.

Weaver K. Magnesium and Migraine. Headache 1990; 30:168.

Faccinetti F, Sances G, Borella P, et al. Magnesium Prophylaxis of Menstrual Migraine: Effects on Intra-cellular Magnesium. Headache 1991; 31:298-304.

Peikert A, Wilimzig C, Kohne-Volland R. Prophylaxis of Migraine with Oral Magnesium: Results from a Prospective, Multi-Center, Placebo-Controlled and Double-Blind Randomized Study. Cephalalgia 1996; 16:257-63.

Pfaffenrath V, Wessely P, Meyer C, et al. Magnesium in the Prophylaxis of Migraine--A Double-Blind, Placebo-Controlled Study. Cephalalgia 1996;16:436-40.

Schoenen J, Lenaerts M, Bastings E. High-dose Riboflavin as a Prophylactic Treatment of Migraine: Results of an Open Pilot Study. Cephalalgia 1994l14:328-9.